Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis

Abstract

The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Psoriatic Arthritis (PsA).

What is claimed is: 
     
         1 . A composition comprising at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, and at least one pharmaceutically acceptable carrier or diluent for use in the safe and effective treatment of active Psoriatic Arthritis, wherein said composition is administered via IV infusion, and wherein at week 14 of treatment patients treated with the anti-TNF antibody achieve a mean change from baseline in one or more criteria selected from the group consisting of: HAQ-DI=−0.60±0.53 SD, enthesitis=−1.87±1.75 SD, dactylitis=−7.8±8.57 SD, SF-36 PCS=8.65±7.60 SD, and SF-36 MCS=5.33±9.95 SD. 
     
     
         2 . The composition according to  claim 1 , wherein said composition is administered such that said anti-TNF antibody is administered at a dose of 2 mg/kg, over 30±10 minutes, at Weeks 0 and 4, then every 8 weeks (q8w) thereafter. 
     
     
         3 . The composition according to  claims 1 - 2 , further comprising administering said composition with or without methotrexate (MTX). 
     
     
         4 . A composition comprising at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, and at least one pharmaceutically acceptable carrier or diluent for use in the safe and effective treatment of active Psoriatic Arthritis, wherein said composition is administered via IV infusion, and wherein at week 24 of treatment patients treated with the anti-TNF antibody achieve a mean change from baseline in vdH-S=−0.36±0.144 SE. 
     
     
         5 . The composition according to  claim 4 , wherein said composition is administered such that said anti-TNF antibody is administered at a dose of 2 mg/kg, over 30±10 minutes, at Weeks 0 and 4, then every 8 weeks (q8w) thereafter. 
     
     
         6 . The composition according to  claims 4 - 5 , further comprising administering said composition with or without methotrexate (MTX). 
     
     
         7 . At least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Psoriatic Arthritis, wherein said anti-TNF antibody is administered via intravenous (IV) infusion, and wherein ≥65% of patients receiving the treatment achieve ACR20 at week 14 of treatment. 
     
     
         8 . The anti-TNF antibody according to  claim 7 , wherein said ≥65% of patients that achieve ACR20 at week 14 of treatment with a treatment difference (improvement compared to placebo) of ≥50%. 
     
     
         9 . The anti-TNF antibody according to  claim 7 - 8 , wherein said antibody is administered at a dose of 2 mg/kg, over 30±10 minutes, at Weeks 0 and 4, and then every 8 weeks (q8w) thereafter. 
     
     
         10 . The anti-TNF antibody according to  claims 7 - 8 , wherein said antibody is administered with or without methotrexate (MTX).